MA31202B1 - Procede de traitement du cancer - Google Patents

Procede de traitement du cancer

Info

Publication number
MA31202B1
MA31202B1 MA32188A MA32188A MA31202B1 MA 31202 B1 MA31202 B1 MA 31202B1 MA 32188 A MA32188 A MA 32188A MA 32188 A MA32188 A MA 32188A MA 31202 B1 MA31202 B1 MA 31202B1
Authority
MA
Morocco
Prior art keywords
way
treat cancer
mammal
human
effective amount
Prior art date
Application number
MA32188A
Other languages
Arabic (ar)
English (en)
Inventor
Connie Lynn Erickson-Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31202(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31202B1 publication Critical patent/MA31202B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de traitement du cancer et des syndromes précancéreux chez un mammifère, y compris chez un être humain en ayant besoin, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un agoniste de récepteur de tpo non-peptidique à un tel mammifère.
MA32188A 2007-02-16 2009-08-31 Procede de traitement du cancer MA31202B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03
PCT/US2008/054046 WO2008101141A2 (fr) 2007-02-16 2008-02-15 Procédé de traitement du cancer

Publications (1)

Publication Number Publication Date
MA31202B1 true MA31202B1 (fr) 2010-02-01

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32188A MA31202B1 (fr) 2007-02-16 2009-08-31 Procede de traitement du cancer

Country Status (27)

Country Link
US (2) US20100075928A1 (fr)
EP (1) EP2124547B1 (fr)
JP (1) JP5511391B2 (fr)
KR (1) KR101447763B1 (fr)
CN (1) CN101662937B (fr)
AR (1) AR065348A1 (fr)
AU (1) AU2008216106B9 (fr)
BR (1) BRPI0807940B8 (fr)
CA (1) CA2678358C (fr)
CR (1) CR10997A (fr)
DK (1) DK2124547T3 (fr)
EA (1) EA017715B1 (fr)
ES (1) ES2675070T3 (fr)
HU (1) HUE038563T2 (fr)
IL (2) IL200319A (fr)
MA (1) MA31202B1 (fr)
MX (1) MX2009008822A (fr)
NZ (1) NZ579068A (fr)
PE (1) PE20081784A1 (fr)
PL (1) PL2124547T3 (fr)
PT (1) PT2124547T (fr)
SI (1) SI2124547T1 (fr)
TR (1) TR201809010T4 (fr)
TW (1) TW200906393A (fr)
UY (1) UY30915A1 (fr)
WO (1) WO2008101141A2 (fr)
ZA (1) ZA200905532B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
JP5393691B2 (ja) * 2007-10-09 2014-01-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ）
EP3127427B1 (fr) 2009-05-29 2020-01-08 Novartis Ag Procédés d'administration de composés agonistes de la thrombopoïétine
CA2808908A1 (fr) * 2010-09-01 2012-03-08 Novartis Ag Association d'inhibiteurs de hdac et de medicaments contre la thrombopenie
US9962370B2 (en) 2013-03-15 2018-05-08 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
AU2017261371B2 (en) * 2016-05-06 2023-07-06 Taris Biomedical Llc Method of treating lower tract urothelial cancer
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (fr) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Ligands du recepteur mpl, leur procede de preparation, medicaments les contenant et leur utilisation pour le traitement et la prevention de la thrombocytopenie et l'anemie
CA2380206A1 (fr) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Compositions medicamenteuses possedant une activite agoniste de la thrombopoietine
EP2087907B1 (fr) * 1999-11-10 2014-09-24 Innatus Corporation Procédé et système pour supprimer l'inhibiteur de cytokine chez les patients
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU2001260661A1 (en) * 2000-05-30 2001-12-11 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
AU2001265188A1 (en) * 2000-05-31 2001-12-11 Genzyme Corporation Therapeutic compounds for ovarian cancer
AU2002236765A1 (en) * 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US7169931B2 (en) 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
BR0206670A (pt) 2001-01-26 2004-02-25 Shionogi & Co Compostos halogenados que exibem agonismo para receptor de trombopoietina
EP1357116A4 (fr) * 2001-02-02 2005-06-01 Yamanouchi Pharma Co Ltd Derive de 2-acylaminothiazole ou son sel
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
AU2002334595B2 (en) * 2001-09-24 2007-03-01 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
KR101010905B1 (ko) 2002-01-18 2011-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아실아미노티아졸 유도체 또는 그 염
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (fr) 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. Nouveau sel d'un derive de 2-acylaminothiazole
EP2387998A1 (fr) 2003-04-29 2011-11-23 Glaxosmithkline LLC Procédés de traitement de maladies/lésions dégénératives
WO2005118551A2 (fr) 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Composes modulant l'activite de la thrombopoietine et methodes associees
MX2007004765A (es) * 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
AU2006318527A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods
EP2001845A2 (fr) 2006-03-15 2008-12-17 Ligand Pharmaceuticals, Inc. Synthese de composes modulant l'activite de la thrombopoietine

Also Published As

Publication number Publication date
AR065348A1 (es) 2009-06-03
PT2124547T (pt) 2018-07-04
EP2124547A2 (fr) 2009-12-02
US20100075928A1 (en) 2010-03-25
DK2124547T3 (en) 2018-07-16
CR10997A (es) 2009-10-16
IL238394A0 (en) 2015-06-30
AU2008216106B9 (en) 2013-09-05
WO2008101141A3 (fr) 2008-10-16
IL200319A (en) 2015-05-31
IL200319A0 (en) 2010-04-29
BRPI0807940B1 (pt) 2020-10-27
MX2009008822A (es) 2009-08-28
CA2678358C (fr) 2015-12-08
EP2124547A4 (fr) 2010-05-05
ZA200905532B (en) 2010-04-28
CA2678358A1 (fr) 2008-08-21
TR201809010T4 (tr) 2018-07-23
CN101662937A (zh) 2010-03-03
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
BRPI0807940A2 (pt) 2013-07-30
ES2675070T3 (es) 2018-07-06
JP5511391B2 (ja) 2014-06-04
PL2124547T3 (pl) 2018-08-31
CN101662937B (zh) 2014-03-12
IL238394B (en) 2018-05-31
TW200906393A (en) 2009-02-16
JP2010519221A (ja) 2010-06-03
HUE038563T2 (hu) 2018-10-29
UY30915A1 (es) 2008-09-02
BRPI0807940B8 (pt) 2021-05-25
EA017715B1 (ru) 2013-02-28
AU2008216106B2 (en) 2013-07-11
PE20081784A1 (es) 2009-01-25
NZ579068A (en) 2012-05-25
WO2008101141A2 (fr) 2008-08-21
EP2124547B1 (fr) 2018-03-28
AU2008216106A1 (en) 2008-08-21
KR101447763B1 (ko) 2014-10-07
SI2124547T1 (en) 2018-08-31
EA200970776A1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
MA31202B1 (fr) Procede de traitement du cancer
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
TW200733976A (en) Method for the treatment of cognitive dysfunction
EA201190042A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
CR10297A (es) &#34;metodos para prevenir y tratar efermedades amiloidogenicas&#34;
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D&#39;UTILISATION DE CEUX-CI
MA32684B1 (fr) Dérivés de picolinamide en tant qu&#39;inhibiteurs de kinase
MA33724B1 (fr) Anticorps neutralisants anti-ngf humain en tant qu&#39;inhibiteurs selectifs de la voie du ngf
MA33295B1 (fr) Nouvelle formulation de diclofénac
EA201100609A1 (ru) Способы лечения воспаления
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l&#39;ibuprofene
MX360147B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
BRPI0518690A2 (pt) tratamento de doenÇa inflamatària do intestino
ECSP099308A (es) Métodos de tratamiento de la depresión
MA31757B1 (fr) Traitement de symptomes vasomoteurs
PH12014501074A1 (en) Methods of using a thiazole derivative
WO2007011873A3 (fr) Procede permettant de traiter des maladies neovasculaires intraoculaires
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2
MA35866B1 (fr) Combinaisons d&#39;azilsartan et de chlorthalidone pour le traitement de patients hypertendus noires